Biogen (BIIB) Tops Q2 EPS by $1.12; Raises Outlook

Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.25, $1.12 better than the analyst estimate of $4.13. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.49 billion.

GUIDANCE:

Biogen sees FY2022 EPS of $15.25-$16.75, versus the consensus of $15.54. Biogen sees FY2022 revenue of $9.9-10.1 billion, versus the consensus of $9.84 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• United Airlines (UAL) Tops Q2 EPS by 14c, Offers Guidance
• Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
• JPMorgan Upgrades BlackRock (BLK) to Overweight